Thursday, January 18, 2018, San Francisco, California, 7:00 PM – 9:30 PM (Pacific Time)

Interactive Tumor Board: Clinical Investigators Discuss Available Research Shaping the Current and Future Treatment of Gastrointestinal Cancers

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

6:30 PM – 7:00 PM (Pacific Time) — Registration and Buffet Dinner
7:00 PM – 9:30 PM (Pacific Time) — Educational Meeting

Meeting Room:
Yerba Buena Ballroom, Salon 1-7 (Lower B2 Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of
Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic, Arizona
Scottsdale, Arizona

Peter C Enzinger, MD
Center for Esophageal and Gastric Cancer
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Heinz-Josef Lenz, MD
Professor of Medicine and Preventive Medicine
J Terrence Lanni Chair in Cancer Research
USC Center for Molecular Pathways and
Drug Discovery
Keck School of Medicine
University of Southern California
Associate Director of Adult Oncology
Co-Director, Colorectal Center
Scientific Director, Cancer Genetics Unit
USC Norris Comprehensive Cancer Center
Los Angeles, California

Eileen M O'Reilly, MD
Associate Director, Clinical Research
David M Rubenstein Center for
Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Michael J Overman, MD
Associate Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute 
Nashville, Tennessee

Virtual Audience Liaison:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2018 Gastrointestinal Cancers Symposium.

6:30 PM – 7:00 PM (Pacific Time) — Registration and Buffet Dinner
7:00 PM – 9:30 PM (Pacific Time) — Educational Meeting

Five GI cancer investigators will serve as the faculty with Dr Johanna Bendell as guest moderator. The agenda will be divided into 5 modules focused on the management of various GI neoplasms, including colorectal, gastric and pancreatic cancer. Each module will feature discussion of actual patients treated within the moderator’s practice and a review of audience polling results centered on the cases and related clinical issues. After each discussion, one of the faculty members will deliver a short presentation reviewing relevant ongoing clinical research. RTP president and medical oncologist Dr Neil Love will participate as a liaison between the attendees and the moderator and faculty. In this capacity, Dr Love will conduct additional live polling and will relay questions submitted by the attendees via a virtual “chat room” to foster additional panel debate.

Detailed agenda to be announced by mid-December.

Topics for Discussion

MODULE 1: Current and Future Treatment of Gastric and Gastroesophageal Junction (GEJ) Cancer

MODULE 2: Potential Role of Immune Checkpoint Inhibitors in Gastric and GEJ Cancer

MODULE 3: Existing, Recently Approved and Investigational Approaches for Patients with Resectable and Unresectable Pancreatic Adenocarcinoma

MODULE 4: Selection and Sequencing of Systemic Therapy for Patients with Metastatic Colorectal Cancer

MODULE 5: Immune Checkpoint Inhibitors in the Management of Metastatic Colorectal Cancer

Target Audience:
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Review recent data on therapeutic advances and changing practice standards in colorectal and noncolorectal GI cancers, and integrate this information as appropriate into current clinical care.
  • Develop long-term care plans for individuals diagnosed with metastatic colorectal cancer, considering the patient’s biomarker profile, tumor location, exposure to prior systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
  • Use HER2 status, clinical factors and patient perspectives to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric/gastroesophageal cancer.
  • Consider age, PS, and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
  • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
  • Describe ongoing research to validate or identify additional biomarkers predictive of response to anti-PD-1/PD-L1 antibodies, and use this information to guide future trial design or routine clinical practice.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents in GI cancers, and counsel appropriately selected patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Lilly and Taiho Oncology Inc.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room:
Yerba Buena Ballroom, Salon 1-7 (Lower B2 Level)

The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2018 Gastrointestinal Cancers Symposium is taking place.


This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow or other healthcare provider involved in the treatment of cancer

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME/CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.